Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Talquetamab is an investigational, off-the-shelf (ready to use), bispecific T-cell engager antibody that targets GPRC5D. PMC J Oncol Pharm Pract. This is the new unmet need in multiple myeloma.. Known in full as G protein-coupled receptor, family C, group 5, member D, the protein found on cancerous plasma cells drew attention over the weekend as Johnson & Johnson unveiled new data for an experimental multiple myeloma treatment. Step-up dose 1 . Multiple myeloma is an incurable blood cancer that affects cells inside a patient's bone marrow. Following our recent Biologics License Application submission to the US FDA, we look forward to working with the agency to make this available as a treatment option in the short term and continuing our longer-term investigations of talquetamab as we aim to develop additional options for patients with this complex blood cancer," said Sen Zhuang, vice president of clinical R&D at Janssen Research & Development. Clinical Updates: Emerging Therapies for Patients With Multiple Myeloma Teclistamab (Tecvayli) for the Treatment of Multiple Myeloma Although all oral symptoms were categorized as grade 1 or 2, they still had a significant effect on quality of life and treatment continuation; dysgeusia was responsible for 3 cases of dose interruptions, 1 case of dose reduction, and 1 treatment discontinuation; dysphagia was the catalyst for 3 cases of treatment interruptions. Now, trials of talquetamab have shown very promising results in people with refractory myeloma. Teclistamab (JNJ-64007957) may be a safe and efficacious treatment option for patients with relapsed/refractory multiple myeloma, according to findings from a phase I study presented at the 2020 American Society of Clinical Oncology . We're not used to seeing that, but something important to keep in mind. Anti-PD1. Talquetamab is a 'first in class' bispecific antibody that targets the GPRC5D, a new target expressed on myeloma cells, and CD3, a protein expressed on T-cells. Methods: In a phase 1 study, we evaluated talquetamab administered intravenously weekly or every other week (in doses from 0.5 to 180 g per kilogram of body weight) or subcutaneously weekly .